Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications
- PMID: 16697768
- PMCID: PMC1800931
- DOI: 10.1016/j.lab.2005.12.006
Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications
References
-
- Hansson GK. Inflammation, atherosclerosis and coronary artery disease. New Engl J Med. 2005;352:1685–1695. - PubMed
-
- Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care. 2005;28:645–652. - PubMed
-
- Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–281. - PubMed
-
- Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253–261. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- DK 61537/DK/NIDDK NIH HHS/United States
- R44 DK062540/DK/NIDDK NIH HHS/United States
- K08 DK061537-04/DK/NIDDK NIH HHS/United States
- DK 62540/DK/NIDDK NIH HHS/United States
- R44 DK062540-03/DK/NIDDK NIH HHS/United States
- R44 DK072587/DK/NIDDK NIH HHS/United States
- R43 DK062540/DK/NIDDK NIH HHS/United States
- R01 DK044513/DK/NIDDK NIH HHS/United States
- R44 DK062540-02/DK/NIDDK NIH HHS/United States
- DK 72587/DK/NIDDK NIH HHS/United States
- DK 44513/DK/NIDDK NIH HHS/United States
- K08 DK061537/DK/NIDDK NIH HHS/United States
- R43 DK072587/DK/NIDDK NIH HHS/United States
- DK 54608/DK/NIDDK NIH HHS/United States
- R43 DK072587-01/DK/NIDDK NIH HHS/United States
